CN Patent

CN117338782A — 哌啶基-吲哚衍生物的用途

Assigned to Novartis AG · Expires 2024-01-05 · 2y expired

What this patent protects

本发明涉及哌啶基‑吲哚衍生物的用途，具体涉及某些哌啶基‑吲哚衍生物在治疗患有补体旁路途径活化相关的病症和疾病(如肾疾病)的患者中的用途，并且特别是在治疗患有C3G(C3肾小球病)和IgAN(免疫球蛋白A肾病)的患者中的用途。

USPTO Abstract

本发明涉及哌啶基‑吲哚衍生物的用途，具体涉及某些哌啶基‑吲哚衍生物在治疗患有补体旁路途径活化相关的病症和疾病(如肾疾病)的患者中的用途，并且特别是在治疗患有C3G(C3肾小球病)和IgAN(免疫球蛋白A肾病)的患者中的用途。

Drugs covered by this patent

iptacopan-hydrochloride (IPTACOPAN HYDROCHLORIDE)

Patent Metadata

Patent number: CN117338782A
Jurisdiction: CN
Classification: —
Expires: 2024-01-05
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.